73 results
6-K
EX-99.1
CALT
Calliditas Therapeutics AB
25 Apr 24
Current report (foreign)
4:06pm
confer-ence, where we had two oral presentations and 2 posters, allowing us to share the exciting long-term Phase 3 data with the nephrology community … of the 2-year eGFR slope from the NefIgard Phase 3 trial predicting long term clinical benefit in a real-world population, adding to the already
6-K
EX-99.1
uunfo dcyr6cqw
6 Mar 24
Current report (foreign)
4:05pm
6-K
EX-99.2
l9wgq6 755o
21 Feb 24
Calliditas Year-end report, January – December 2023
4:05pm
6-K
EX-99.1
ruo4a5m8l
20 Dec 23
Current report (foreign)
5:13pm
6-K
EX-99.2
9eeyw90d3gqma7d73na8
7 Nov 23
Interim Report January – September 2023 Q3
4:05pm
6-K
EX-99.1
020q0z45 pnzg
7 Nov 23
Interim Report January – September 2023 Q3
4:05pm
6-K
EX-99.1
o2xb0q
17 Aug 23
Filing for full approval of TARPEYO
4:05pm
S-8
EX-5.1
upv663 gj38
12 Jun 23
Registration of securities for employees
4:06pm
S-8
EX-99.6
cnew0p8
12 Jun 23
Registration of securities for employees
4:06pm
S-8
ft58fvxj
12 Jun 23
Registration of securities for employees
4:06pm
6-K
EX-99.1
q83ffz
30 May 23
Adoption of income statement and balance sheet for the financial year 2022 and discharge from liability
4:21pm
6-K
EX-99.1
m8h2k1qe2gmpo
16 May 23
Current report (foreign)
4:05pm
6-K
EX-99.3
03gx3x 24wlkmg3l
28 Apr 23
Current report (foreign)
4:05pm
6-K
EX-99.1
408g7
28 Apr 23
Current report (foreign)
4:05pm